Evidence map›Paper›PMID 32657043›Full record

ArticleESC heart failure2020

Danon disease is an underdiagnosed cause of advanced heart failure in young female patients: a LAMP2 flow cytometric study.

Jiri Gurka, Lenka Piherova, Filip Majer, Anna Chaloupka, Daniela Zakova, Ondrej Pelak, Alice Krebsova, Petr Peichl, Jan Krejci, Tomas Freiberger and 5 more

Open access · goldAbstract read
In one paragraph

Article in ESC heart failure, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Jiri GurkaDepartment of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Lenka PiherovaResearch Unit for Rare Diseases, Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Filip MajerResearch Unit for Rare Diseases, Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Anna Chaloupka1st Internal Cardioangiologic Clinic, Faculty of Medicine, Masaryk University and St. Anne's University Hospital, Brno, Czech Republic.
Daniela ZakovaCentre of Cardiovascular and Transplant Surgery, St. Annes University Hospital, Brno, Czech Republic.
Ondrej PelakDepartment of Paediatric Haematology and Oncology, Childhood Leukaemia Investigation Prague, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
Alice KrebsovaDepartment of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Petr PeichlDepartment of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Jan Krejci1st Internal Cardioangiologic Clinic, Faculty of Medicine, Masaryk University and St. Anne's University Hospital, Brno, Czech Republic.
Tomas FreibergerCentre of Cardiovascular and Transplant Surgery, St. Annes University Hospital, Brno, Czech Republic.
Vojtech MelenovskyDepartment of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Josef KautznerDepartment of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Tomas KalinaDepartment of Paediatric Haematology and Oncology, Childhood Leukaemia Investigation Prague, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
Jakub SikoraResearch Unit for Rare Diseases, Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Milos KubanekDepartment of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Institute of Clinical and Experimental Medicine · CZCharles University · CZUniversity Hospital Brno · CZGeneral University Hospital in Prague · CZSt. Anne's University Hospital Brno · CZ

Funding

Charles University in Prague SVV 260367, UNCE 204064, PROGRES Q26/LF1Ministerstvo Zdravotnictví Ceské Republiky [MZ 15-27682A], [NV19-08-00122], IPO 00023001.Ministry of Health of the Czech Republic MZ 15-27682AMinistry of Health of the Czech Republic NV19-08-00122
6 · The paper itself

Abstract

aimsDanon disease (DD) is a rare X-linked disorder caused by mutations in the lysosomal-associated membrane protein type 2 gene (LAMP2). DD is difficult to distinguish from other causes of dilated or hypertrophic cardiomyopathy (HCM) in female patients. As DD female patients regularly progress into advanced heart failure (AHF) aged 20-40 years, their early identification is critical to improve patient survival and facilitate genetic counselling. In this study, we evaluated the prevalence of DD among female patients with non-ischemic cardiomyopathy, who reached AHF and were younger than 40 years. METHODS AND

resultsThe study cohort comprised 60 female patients: 47 (78%) heart transplant recipients, 2 (3%) patients treated with ventricular assist device, and 11 (18%) patients undergoing pre-transplant assessment. Aetiology of the cardiomyopathy was known in 15 patients (including two DD patients). LAMP2 expression in peripheral white blood cells (WBC) was tested by flow cytometry (FC) in the remaining 45 female patients. Whole exome sequencing was used as an alternative independent testing method to FC. Five additional female DD patients (two with different novel LAMP2 mutations) were identified by FC. The total prevalence of DD in this cohort was 12%. HCM phenotype (57% vs. 9%,

conclusionsDanon disease is an underdiagnosed cause of AHF in young female patients. LAMP2 expression testing in peripheral WBCs by FC can be used as an effective screening/diagnostic tool to identify DD in this patient population.

Indexed as

Cardiomyopathy, HypertrophicGlycogen Storage Disease Type IIbHeart FailureFemaleHumansLysosomal-Associated Membrane Protein 2PhenotypeLAMP2 protein, humanLysosomal-Associated Membrane Protein 2Advanced heart failureDanon diseaseLysosomal-associated membrane protein type 2ScreeningWhite blood cells

Identifiers

PMID32657043
PMCPMC7524080
OpenAlexW3040786329

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.